<DOC>
	<DOCNO>NCT00681967</DOCNO>
	<brief_summary>To evaluate feasibility safety ( cohort 1 ) postoperative standard fractionation radiotherapy plus Iressa ( cohort 2 ) hyperfractionated radiotherapy plus cisplatin Iressa</brief_summary>
	<brief_title>Postoperative Radiotherapy Plus Iressa Radiotherapy Plus Cisplatin Iressa Advanced Head &amp; Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Written inform consent Age 18 year Histologically proven squamous cell cancer head &amp; neck ( SCCHN ) Indication postoperative Radiotherapy : pT3 , pT4 , pN2b , pN2c , pN3 Hypersensitivity ZD1839 excipients product Tumour stage M1 Coexisting malignancy diagnose within last 5 year . Exceptions : basal cell carcinoma , cervical cancer situ Absolute neutrophil count &lt; 1.5 x 109</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>squamous cell cancer head &amp; neck</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>IRESSA</keyword>
	<keyword>EGFR Inhibitor</keyword>
	<keyword>EGFR-tyrosine kinase inhibitor</keyword>
	<keyword>Subjects histologically proven squamous cell cancer head &amp; neck</keyword>
	<keyword>Cohort 1 : qualifying postoperative radiotherapy</keyword>
	<keyword>( pT3 , pT4 , pN2b , pN2c , pN3 ) .</keyword>
	<keyword>Cohort 2 : qualifying definite chemoradiotherapy</keyword>
	<keyword>( Lateral oropharynx , tonsil : T1N2b-3 , T2N1-3 , T3any N ;</keyword>
	<keyword>Base tongue , vallecula : T1N1-3 , T2-4 N ; Oral cavity ,</keyword>
	<keyword>glottic supraglottic larynx ; Any TN1-3 , T3-4 N ;</keyword>
	<keyword>Hypopharynx : T1N1-3 , T2-4 N )</keyword>
</DOC>